Retinoic Acid Receptor alpha/beta/gamma Recombinant Rabbit Monoclonal Antibody [PSH08-74]
cat.: HA723026
| Product Type: | Recombinant Rabbit monoclonal IgG, primary antibodies |
|---|---|
| Species reactivity: | Human |
| Applications: | WB |
| Clonality: | Monoclonal |
| Clone number: | PSH08-74 |
| Form: | Liquid |
| Storage condition: | Shipped at 4℃. Store at +4℃ short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20℃ long term. |
| Storage buffer: | PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1ug/ul |
| Purification: | Protein A affinity purified. |
| Molecular weight: | Predicted band size: 50 kDa |
| Isotype: | IgG |
| Immunogen: | Recombinant protein within human RARG aa 155-454. |
| Positive control: | SK-Br-3 cell lysate, T-47D cell lysate, A375 cell lysate, HeLa cell lysate. |
| Subcellular location: | Nucleus, Cytoplasm. |
| Recommended Dilutions:
WB |
1:1,000-1:5,000 |
| Uniprot #: | SwissProt: P10276 Human | P10826 Human | P13631 Human | P11416 Mouse | P22605 Mouse | P18911 Mouse Entrez Gene: 24705 Rat | 24706 Rat | 685072 Rat |
| Alternative names: | NR1B1 Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein Nuclear receptor subfamily 1 group B member 1 Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form RAR alpha RAR RAR-alpha rara RARA_HUMAN RARalpha RARalpha1 Retinoic acid nuclear receptor alpha variant 1 Retinoic acid nuclear receptor alpha variant 2 Retinoic acid receptor alpha Retinoic acid receptor alpha polypeptide HAP HBV-activated protein NR1B2 Nuclear receptor subfamily 1 group B member 2 RAR B RAR beta RAR epsilon RAR-beta RAR-epsilon RARB RARB_HUMAN Retinoic acid receptor beta 2 Retinoic acid receptor beta 4 Retinoic acid receptor beta 5 Retinoic acid receptor beta Retinoic acid receptor beta polypeptide RRB2 |
Images
|
Fig1:
Western blot analysis of Retinoic Acid Receptor alpha/beta/gamma on different lysates with Rabbit anti-Retinoic Acid Receptor alpha/beta/gamma antibody (HA723026) at 1/1,000 dilution. Lane 1: SK-Br-3 cell lysate Lane 2: T-47D cell lysate Lane 3: A375 cell lysate Lane 4: HeLa cell lysate Lysates/proteins at 20 µg/Lane. Predicted band size: 50 kDa Observed band size: 58 kDa Exposure time: 3 minutes; ECL: K1801; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (HA723026) at 1/1,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. |
|
Fig2:
Western blot analysis of Retinoic Acid Receptor alpha/beta/gamma on different lysates with Rabbit anti-Retinoic Acid Receptor alpha/beta/gamma antibody (HA723026) at 1/1,000 dilution. Lane 1: Human RARG recombinant protein, 20ng/Lane Lane 2: Human RARA recombinant protein, 20ng/Lane Exposure time: 2 seconds; ECL: K1801; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (HA723026) at 1/1,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. |
|
Fig3:
Western blot analysis of Retinoic Acid Receptor alpha/beta/gamma on different lysates with Rabbit anti-Retinoic Acid Receptor alpha/beta/gamma antibody (HA723026) at 1/5,000 dilution. Lane 1: Human RARG recombinant protein, 20ng/Lane Lane 2: Human RARB recombinant protein, 20ng/Lane Exposure time: 20 seconds; ECL: K1801; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (HA723026) at 1/5,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.